This article addresses some issues involved in meeting regulatory characterization expectations for biosimilars by answering the following questions: What regulatory guidelines are associated with structural characterization and comparability/biosimilarity testing? What complicates the characterization of complex (glyco)protein products? When is analytical characterization required? And which techniques (old and new) are suitable for this application?
Building No. 1, Harrowdene Office Park, Western Service Road,
Woodmead, Sandton Western Service Road, 2191,
Woodmead, South Africa